Skip to Content

'
Lajos Pusztai, M.D., DPhil.

Present Title & Affiliation

Primary Appointment

Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1987 Semmelweis University of Medicine, Budapest, Hungary, MD, Medicine

Postgraduate Training

7/1996-12/1998 Fellow, Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
7/1993-7/1996 Intern/Resident, Internal Medicine, University of Rochester, St. Mary's Hospital, NY, NY, Dr. Richard Wagner
10/1989-6/1993 Post-Doctoral Research Fellow, John Radcliffe Hospital, Oxford, United Kingdom, Dr. James O'D McGee
11/1987-8/1988 Postdoctoral Research Assistant, Hungarian Academy of Sciences, Budapest, Hungary, Dr. Makara

Board Certifications

1/1999 Subspecialty Board of Medical Oncology
1/1996 American Board of Internal Medicine

Selected Publications

Peer-Reviewed Original Research Articles
1. Pusztai L, Jeong JH, Gong Y, Ross JS, Kim C, Paik S, Rouzier R, Andre F, Hortobagyi GN, Wolmark N, Symmans WF. Evaluation of microtubule associated protein-tau expression as prognostic and predictive marker in NSABP-B 28 randomized clinical trial. J Clin Oncol. In Press. PMID: 19667268.
2. Liedtke C, Gonzalez-Angulo AM, Pusztai L, Hortobagyi GN, Kau SW, Hsu L, Symmans WF, Woodward W, Albarracin C, Kiesel L. Prognostic impact of discordance between triple receptor measurements in primary and recurrent breast cancer. Ann Oncol. In Press. PMID: 19596702.
3. Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, Kuerer H, Hortobagyi GN, Piccart-Gebhart M, Sotiriou C, Pusztai L. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 27(19):3185-3191, 2009. PMID: 19364972.
4. Tordai A, Liedtke C, Pusztai L. Metastatic gene signatures and emerging novel prognostic tests in the managment of early stage breast cancer. Clin Exp Metastasis:DOI 10.1007/s10585-009-9261-z, 2009. PMID: 19381845.
5. Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, Richon C, Yan K, Wang B, Vassal G, Delaloge S, Hortobagyi GN, Symmans WF, Lazar V, Pusztai L. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 15(2):441-451, 2009. PMID: 19147748.
6. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufman M. T-cell metagene predicts a favorable prognosis in estrogen receptor negative and HER2 positive breast cancers. Breast Cancer Res 11(2):R15, 2009. PMID: 19272155.
7. Stemke-Haloe K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Zhi, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN and AKT mutations in breast cancer. Cancer Res 68(15):6084-6091, 2008. PMID: 18676830.
8. Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat 108(2):183-90, 2008. PMID: 17468948.
9. Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, Pusztai L, Esteva FJ, Dawood S, Green MC, Hortobagyi GN, Symmans WF. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol 19(12):2020-5, 2008. PMID: 18667396.
10. Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: Clinical activity and biological correlations. Ann Oncol 19(10):1713-1719, 2008. PMID: 18515258.
11. Wilson NM, Espirito JL, Valero V, Pusztai L. Paclitaxel-induced sickle cell crisis. Am J Health Syst Pharm 65(14):1333-1336, 2008. PMID: 18593679.
12. Liedtke C, Cardone L, Tordai A, Yan K, Gomez HL, Figueroa LJ, Hubbard RE, Valero V, Souchon EA, Symmans WF, Hortobagyi GN, Bardelli A, Pusztai L. PIK3CA activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res 10(2):R27, 2008. PMID: 18371219.
13. Natowicz R, Incitti R, Horta EG, Charles B, Guinot P, Yan K, Coutant C, Andre F, Pusztai L, Rouzier R. Prediction of the outcome of preoperative chemotherapy in breast cancer by using DNA probes that provide information on both complete and incomplete responses. BMC Bioinformatics 9:149, 2008. PMID: 18366635.
14. Wollf AC, Berry D Carey LA, Colleoni M, Dowsett M, Ellis M, Garber JE, Mankoff D, Paik S, Pusztai L, Smith ML, Zujewski JA. Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol 26(5):806-813, 2008. PMID: 18258990.
15. Peintinger F, Kuerer HM, McGuire SE, Bassett R, Pusztai L, Symmans WF. Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer. Br J Surg 95(4):433-437, 2008. PMID: 18161887.

Last updated: 9/11/2009